Ameet Mallik has served as ADC Therapeutics' Chief Executive Officer since May 2022 and as a member of the board of directors since June 2022. From 2005 to April 2021 he held various positions at Novartis, including Executive Vice President and Head of U.S. Oncology (2017-2021) and Senior Vice President, Head of Global Marketing, Value and Access (2015-2017); he earlier held commercial roles at Sandoz and was an Associate Principal at McKinsey. From May 2021 to January 2022 he served as Chief Executive Officer of Rafael Holdings. Mr. Mallik holds an M.B.A. from The Wharton School at the University of Pennsylvania and an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University.